EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations

Balázs Jóri iD, Christine Vössing, Judith Pirngruber, Eva Maria Willing iD, Kathrin Arndt, Markus Falk iD, Markus Tiemann, Lukas C Heukamp, Petra Hoffknecht

Current Oncology · 2023

DOI: 10.3390/curroncol30100635 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Current Oncology, 2023. Verfasst von Balázs Jóri und 8 weiteren Autor:innen. Beteiligte Einrichtung: Lungenkrebsmedizin Oldenburg, Georgstraße 12, 26121 Oldenburg, Germany. Hauptthemen laut MEDLINE: Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

EGFR-mutant lung cancers develop a wide range of potential resistance alterations under therapy with the third-generation EGFR tyrosine kinase inhibitor osimertinib. MET amplification ranks among the most common acquired resistance alterations and is currently being investigated as a therapeutic target in several studies. Nevertheless, targeted therapy of MET might similarly result in acquired resistance by point mutations in MET, which further expands therapeutic and diagnostic challenges. Here, we report a 50-year-old male patient with EGFR-mutant lung adenocarcinoma and stepwise acquired resistance by a focal amplification of MET followed by D1246N (D1228N), D1246H (D1228H), and L1213V (L1195V) point mutations in MET, all detected by NGS. The patient successfully responded to the combined and sequential treatment of osimertinib, osimertinib/crizotinib, and third-line osimertinib/cabozantinib. This case highlights the importance of well-designed, sequential molecular diagnostic analyses and the personalized treatment of patients with acquired resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsHumansMaleMiddle AgedCrizotinibDrug Resistance, NeoplasmErbB ReceptorsMutationProtein Kinase InhibitorsProto-Oncogene Proteins c-metAnilidesPyridinesAcrylamidesAniline CompoundsIndolesPyrimidines

Stichwörter der Autor:innen

D1228HD1228ND1246HD1246NL1195VL1213VNGSc-METcabozantinibcopy number callingcrizotinibfocal amplificationhybrid captureosimertinibresistance

Substanzen

CrizotinibErbB ReceptorsProtein Kinase InhibitorsProto-Oncogene Proteins c-metcabozantinibAnilidesPyridinesosimertinibAcrylamidesAniline Compounds

Autor:innen und Institutionen

  • Lungenkrebsmedizin Oldenburg, Georgstraße 12, 26121 Oldenburg, Germany.
  • Institut für Hämatopathologie Hamburg, Fangdieckstraße 75A, 22547 Hamburg, Germany.
  • Department of Thorax Oncology, Niels-Stensen-Kliniken, Franziskus-Hospital Harderberg Alte, Rothen-Felder Straße 23, 49124 Georgsmarienhütte, Germany.

ORCID-Profile: Balázs Jóri, Eva Maria Willing, Markus Falk

Zitieren

APA

Jóri, B., Vössing, C., Pirngruber, J., Willing, E. M., Arndt, K., Falk, M., Tiemann, M., Heukamp, L. C., & Hoffknecht, P. (2023). The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations. Current Oncology. https://doi.org/10.3390/curroncol30100635

Vancouver

Jóri B, Vössing C, Pirngruber J, Willing EM, Arndt K, Falk M, et al. The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations. Current Oncology. 2023. doi:10.3390/curroncol30100635

BibTeX
@article{Jri2023,
  author = {Jóri, Balázs and Vössing, Christine and Pirngruber, Judith and Willing, Eva Maria and Arndt, Kathrin and Falk, Markus and Tiemann, Markus and Heukamp, Lukas C and Hoffknecht, Petra},
  title = {The Combined Therapy of Cabozantinib, Crizotinib, and Osimertinib in a Lung Cancer Patient with Acquired MET Amplification and Resistance Mutations},
  journal = {Current Oncology},
  year = {2023},
  doi = {10.3390/curroncol30100635}
}
Kostenlos starten →